Recent Updates — CHRN
ChronoScale Holdings Corporation reported fiscal first quarter 2027 revenue of $41.5 million, a 148% increase from the prior-year period's $16.7 million. The company posted a net loss of $26.4 million and adjusted EBITDA of $5.9 million. Following the business combination completed in May 2026, ChronoScale classified its legacy Ekso Bionics business as held for sale and subsequently completed the sale of that unit on September 30, 2026. The company also secured a 50 MW AI compute deployment with Microsoft and entered strategic partnerships with Nutanix and Baseten Labs. ChronoScale operates an accelerated compute platform purpose-built to support demanding artificial intelligence workloads.
Scott Davis resigned as a member of the Board and former CEO of Ekso Bionics, effective October 3, 2026, upon the completion of ChronoScale Holdings' sale of its wholly owned subsidiary. In connection with the transaction, the Company granted Mr. Davis 51,626 fully vested restricted stock units and entered into a release agreement entitling him to a $709,500 lump sum cash payment within 30 days. The resignation was not caused by any disagreements between the parties. ChronoScale Holdings Corp operates in the technology sector.
ChronoScale Holdings completed the sale of its Ekso Bionics subsidiary on September 30, 2026. Concurrently, the company announced expanded agreements with existing and new AI infrastructure customers, projecting a total contracted annualized run-rate revenue of $1 billion by calendar Q3 2027. The divestiture allows ChronoScale to focus resources on its core accelerated compute business. Additionally, Jason C. Jones was terminated as Chief Operating Officer of Ekso in connection with the transaction and received severance benefits including a lump-sum payment of $243,750 and nine months of COBRA coverage. The company also filed a Withdrawal of Designation for Series B Convertible Preferred Stock, which had no shares outstanding. ChronoScale operates in the artificial intelligence infrastructure sector, providing scalable GPU-based accelerated compute platforms.
ChronoScale Holdings Corp's subsidiary, ChronoScale Intermediate, LLC, entered into a First Amendment to its Secured Promissory Note and Security Agreement with B. Riley Commercial Capital, LLC. The amendment extends the maturity date of the $2.0 million term loan from the earlier of the 12-month anniversary or equity proceeds receipt to November 12, 2026. It also permits the sale of the guarantor entity, Ekso Bionics, Inc., as a permitted disposition. The company operates in the medical device and bionic exoskeleton industry.
ChronoScale Holdings Corporation announced a press release on August 27, 2026, detailing its strategic partnership with Microsoft for a planned 50-megawatt AI compute deployment in North America. The project utilizes NVIDIA GB300 NVL72 systems and advanced liquid-cooling infrastructure to support high-density artificial intelligence workloads. Additionally, the company extended the term of this two-year strategic partnership with Microsoft from two years to three years. ChronoScale Holdings Corporation operates as an accelerated compute platform purpose-built to support demanding artificial intelligence workloads.
On July 1, 2026, ChronoScale Corp completed a holding company formation transaction, creating ChronoScale Holdings Corporation as the new public parent company. ChronoScale Corporation converted into ChronoScale Intermediate LLC and Applied Digital Cloud Corporation was renamed ChronoScale Corporation, both becoming wholly-owned subsidiaries of the new parent. Each share of common and Series B Preferred stock was converted 1-for-1 into shares of ChronoScale Holdings, with no dilution to shareholders. Andrew Schaap was appointed to the Board of Directors on June 29, 2026. The company continues to trade on Nasdaq under the ticker symbol 'CHRN'. ChronoScale operates in the technology sector, providing cloud and digital infrastructure services.